US EditionInstylla Initiates Commercial Launch with First Use of the Embrace™ Hydrogel Embolic System
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Instylla announces first commercial use of the Embrace hydrogel embolic system
Embrace hydrogel embolic system Instylla today announced that Ripal Gandhi (Baptist Health South Florida, Coral Gables, USA) has completed the first commercial procedure using the Embrace hydrogel embolic system (HES). “Ongoing innovation is fundamental to how we continue to advance interventional radiology,” said Gandhi. “Our field relies on tools that allow us to treat complex disease with greater precision and procedural confidence. In this c…
Instylla’s Embrace Hydrogel Embolic System Launched
January 28, 2026—Instylla, Inc., a developer of resorbable embolics for peripheral vascular embolization, announced the completion of the first commercial procedure using the company’s Embrace hydrogel embolic system (HES). Interventional oncologist Ripal Gandhi, MD, from Miami Vascular Specialists in Miami, Florida, performed the first procedure. “Ongoing innovation is fundamental to how we continue to advance interventional radiology,” comment…
Instylla Initiates Commercial Launch with First Use of the Embrace™ Hydrogel Embolic System
Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium